Kyowa Kirin (TSE:4151) has come into focus after a broad rethink of pharmaceutical valuations in Tokyo. This has drawn attention to how its share performance lines up with its current earnings profile and research pipeline.
Over the past few months, Kyowa Kirin's share price has come under pressure, with a 30 day share price return of down 11.87% and a 90 day move of down 11.26%, even though the 1 year total shareholder return is slightly positive at 0.49% including dividends. Recent weakness suggests some investors are reassessing near term risks around earnings and the development pipeline. At the same time, the longer multi year total shareholder returns, down 7.85% over three years and down 37.45% over five years, frame today's ¥2,261.5 share price within a tougher long run performance record.
Compare Kyowa Kirin's recent pullback with other hand picked healthcare stocks under pressure by scanning the 10 healthcare AI stocks that our filters surface for closer review.
Bulls point to Kyowa Kirin's earnings profile and late stage pipeline, while bears see a weak multi year share record and modest discount to analyst targets. Which story does the valuation actually support?
Price-to-Earnings of 14.6x: Is it justified?
Kyowa Kirin currently trades on a P/E of 14.6x, which leaves the share price of ¥2,261.5 looking modestly below some valuation markers but only slightly above the broader Japanese pharmaceuticals average.
The P/E ratio compares the current share price with earnings per share and gives a quick sense of how much investors pay for each unit of profit. For a research driven pharmaceutical group like Kyowa Kirin, this measure often reflects how confident the market is in the sustainability of current earnings and the potential of the late stage pipeline.
On one hand, the stock is described as good value versus an estimated fair P/E of 22.5x and also looks inexpensive compared with a peer average of 15.8x. That kind of gap suggests the market is pricing Kyowa Kirin more cautiously than both the regression based fair multiple and similar companies, even though earnings growth over the past year is reported as very large at 111.7% and ahead of the sector's 13% figure.
On the other hand, the same data flags Kyowa Kirin as slightly expensive against the broader JP Pharmaceuticals industry P/E of 14.4x. This is a narrow premium that implies investors are not assigning a deep discount despite the weaker recent share returns versus the market and sector. If sentiment or expectations shift closer to the 22.5x fair multiple, that would mark a material re rating from where the stock trades today.
Explore the SWS fair ratio for Kyowa Kirin.
Result: Price-to-Earnings of 14.6x (UNDERVALUED)
Still, Kyowa Kirin faces a weak five year shareholder record, and a minimal 0.9% discount to analyst targets that could cap enthusiasm if sentiment stays cautious.
Find out about the key risks to this Kyowa Kirin narrative .
Another View on Kyowa Kirin's Value
The first look at Kyowa Kirin focused on its P/E of 14.6x. A second lens comes from the SWS DCF model, which puts fair value at ¥3,679.22 per share versus the current ¥2,261.5 price. That comparison suggests a large gap between the model's estimate and the market price. So which signal should carry more weight for you right now?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out Kyowa Kirin for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 17 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Sentiment around Kyowa Kirin is clearly mixed right now, so it helps to move quickly and weigh the evidence on your own terms. To see what the current optimism is focused on, review the 4 key rewards .
Looking for more Kyowa Kirin style investment ideas?
If Kyowa Kirin has you thinking more broadly about opportunities, do not stop here. The market rarely waits for investors who stay on the sidelines.
-
Target potential mispricings by scanning a curated pool of attractively valued companies through the 17 high quality undervalued stocks .
-
Strengthen your income game by reviewing a focused set of high yield candidates via the 15 dividend fortresses .
-
Protect the downside by checking a filtered universe of resilient businesses using the 21 resilient stocks with low risk scores .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 4151.T .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
